Skip to main content

Table 3 Correlation between clinical, biological and ultrasound data and serum biomarkers

From: Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers

  Ultrasound-defined synovitis SH ≥2 PDUS ≥1 ACPA titers RF titers CRP DAS28-ESR DAS28-CRP
  R 2 P valuea R 2 P valuea R 2 P valuea R 2 P valuea R 2 P valuea R 2 P valuea R 2 P valuea R 2 P valuea
Activin A 0.234 0.085 0.228 0.093 0.164 0.231 0.409 0.002 -0.000 0.973 0.183 0.181 0.095 0.486 0.199 0.144
ANG 0.213 0.117 0.214 0.115 0.150 0.274 0.275 0.042 0.157 0.250 0.078 0.567 0.054 0.691 0.273 0.044
ANG-2 0.283 0.036 0.214 0.115 0.059 0.666 0.078 0.567 -0.130 0.314 0.081 0.553 0.001 0.989 0.189 0.165
ANG -0.210 0.109 -0.090 0.513 -0.295 0.029 -0.010 0.908 0.342 0.011 0.083 0.544 0.043 0.751 -0.250 0.064
ANGPTL4 -0.060 0.628 -0.010 0.920 -0.110 0.387 0.116 0.398 0.268 0.048 0.352 0.008 -0.190 0.160 -0.050 0.714
bFGF 0.366 0.006 0.265 0.050 0.264 0.051 0.335 0.012 1.000 0.094 0.096 0.485 -0.030 0.825 0.186 0.173
CXCL16 0.006 0.960 -0.040 0.738 0,066 0,629 0.251 0.064 -0.030 0.787 0.283 0.036 0.003 0.978 0.067 0.626
ENA-78 0.013 0.920 -0.060 0.639 0,019 0,890 0.164 0.231 0.083 0.544 0.035 0.795 0.400 0.002 0.000 0.968
GRO 0.128 0.350 0.079 0.565 -0,010 0,888 0.341 0.011 0.090 0.510 0.054 0.693 0.140 0.308 0.064 0.641
IL-17 F 0.023 0.868 0.050 0.713 0,042 0,756 0.206 0.130 0.083 0.573 0.358 0.007 -0.090 0.502 0.098 0.474
IL-18 0.250 0.065 0.154 0.259 0,188 0,169 0.323 0.016 0.537 <0.001 b 0.190 0.163 -0.080 0.528 0.106 0.441
IL-20 0.227 0.095 0.193 0.156 0,133 0,332 0.409 0.002 0.306 0.023 0.097 0.481 0.049 0.719 0.195 0.153
IL-33 0.027 0.841 0.076 0.580 0,014 0,918 0.291 0.031 0.310 0.021 0.323 0.016 -0.160 0.220 0.107 0.433
MMP-2 0.301 0.025 0.268 0.048 0,178 0,192 0.368 0.006 0.454 <0.001 b -0.000 0.988 0.002 0.987 0.166 0.225
PlGF 0.276 0.041 0.207 0.128 0,202 0,138 0.354 0.008 0.535 <0.001 b 0.162 0.237 0.106 0.439 0.207 0.128
SDF-1 0.288 0.033 0.212 0.119 0,214 0,116 0.359 0.007 0.167 0.222 0.144 0.294 0.074 0.587 0.178 0.193
TGF-β1 0.232 0.088 0.298 0.027 0,085 0,534 0.042 0.758 0.263 0.052 0.217 0.110 -0.100 0.443 0.211 0.121
Tie-1 0.217 0.111 0.224 0.100 0,070 0,610 0.439 0.001 0.574 <0.001 b 0.130 0.343 0.026 0.848 0.209 0.125
Tie-2 0.138 0.315 0.191 0.161 0,011 0,931 0.418 0.001 0.396 0.003 0.129 0.345 0.035 0.796 0.168 0.219
TNFα 0.101 0.462 0.163 0.232 -0,030 0,809 0.265 0.050 0.514 <0.001 b 0.124 0.365 -0.040 0.750 0.078 0.569
VEGF 0.071 0.605 0.039 0.776 0,133 0,332 0.114 0.405 0.480 <0.001 b 0.099 0.470 -0.288 0.033 -0.200 0.129
VEGFR-1 0.174 0.202 0.219 0.108 0,078 0,569 0.367 0.006 0.594 <0.001 b 0.083 0.547 0.151 0.270 0.266 0.049
VEGF-D 0.324 0.016 0.239 0.078 0,157 0,251 0.327 0.015 0.264 0.051 0.118 0.388 -0.000 0.954 0.100 0.467
  1. aSpearman’s nonparametric correlation. bP <0.01 adjusted for multiple testing (Bonferroni). ACPA, anti-cyclic citrullinated peptide/protein antibody; ANG, angiopoietin; ANGPTL4, angiopoietin-like protein-4; bFGF, basic fibroblast growth factor; CXCL, CC-chemokine ligand; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ENA-78, epithelial cell-derived neutrophil-activating peptide-78; ESR, erythrocyte sedimentation rate; GRO, growth-related oncogene; IL, interleukin; MMP, matrix metalloproteinase; PDUS, power Doppler ultrasound; PlGF, placental growth factor; RF, rheumatoid factor; SDF-1, stromal-cell derived factor-1; SH, synovial hypertrophy; TGF-β1, transforming growth factor beta-1; Tie, tyrosine-kinase with immunoglobulin-like and endothelial growth factor-like domains; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.